Search
01/11/2025
Consensus on acromegaly therapeutic outcomes: an update
Melmed, S, di Filippo, L, Fleseriu, M, Mercado, M, Karavitaki, N, Gurnell, M, Salvatori, R, Tsagarakis, S, Losa, M, Maffei, P, Pereira, AM, Geer, EB, Katznelson, L, van der Lely, AJ, Bollerslev, J, Esposito, D, Webb, SM, Zatelli, MC, Valassi, E, Neggers, S, Chanson, P, Ho, KKY, Ioachimescu, AG, Biller, BMK, Samson, SL, Kaiser, UB, Schilbach, K, Luque, RM, Casanueva, FF, Shimon, I, Boguszewski, CL, Biermasz, N, Colao, A, Pirchio, R, Lamberts, SWJ, Kadioglu, P, Buchfelder, M, Frara, S, Chiloiro, S, Petersenn, S, Gadelha, MR, Puig-Domingo, M, Luger, A, Brue, T, Beckers, A, Ferone, D, Clemmons, DR, Greenman, Y, Marazuela, M, Mortini, P, Strasburger, CJ, Giustina, A. Consensus on acromegaly therapeutic outcomes: an update. Nature Reviews Endocrinology. 2025; 21(11)DOI:10.1038/s41574-025-01148-2. PMID:40804505. IF:40.000(Q1/1D).
01/11/2025
A Metagenomics Approach to Frailty in Patients With Cirrhosis Undergoing a Multifactorial Intervention
Vega-Abellaneda, S, Román, E, Soler, Z, Ortiz, MA, Rossi, G, Biagini, L, Sánchez, E, Pons-Tarin, M, Laghi, L, Mengucci, C, Kaur, N, Poca, M, Cuyàs, B, Serrano-Gomez, G, Alvarado, E, Manichanh, C, Soriano, G. A Metagenomics Approach to Frailty in Patients With Cirrhosis Undergoing a Multifactorial Intervention. LIVER INTERNATIONAL. 2025; 45(12)DOI:10.1111/liv.70418. PMID:41174950. IF:5.200(Q1/2D).
01/11/2025
First-Line Osimertinib in a Patient Having NSCLC With a Rare Duplication Mutation in the EGFR Exon 19 Region (NM_005228.5:c.2214_2231dup p.(Ile740_Lys745dup))
Portu, M, Martinez-Recio, S, Barba, A, Gonzalez, A, López, L, Catasús, L, Majem, M. First-Line Osimertinib in a Patient Having NSCLC With a Rare Duplication Mutation in the EGFR Exon 19 Region (NM_005228.5:c.2214_2231dup p.(Ile740_Lys745dup)). Clinical Lung Cancer. 2025; 26(7)DOI:10.1016/j.clic.2025.07.013. PMID:40774920. IF:3.300(Q2/4D).
01/11/2025
Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024
Cardozo, AR, Kesselheim, A, Tibau, A. Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1886. PMID:. IF:65.400(Q1/1D).
01/11/2025
Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021
Cardozo, AR, Tibau, A, Liu, I, Han, J, Cliff, E, Kesselheim, A. Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2894. PMID:. IF:65.400(Q1/1D).
01/11/2025
CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas
Martin-Broto, J, Ospina, GM, Garcia, AS, Trufero, JM, Martinez-Garcia, J, Fidalgo, JAP, Morales, CMV, Jurado, JC, Ledesma, P, Grifman, M, Moura, DD, Muñiz, NH. CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3354. PMID:. IF:65.400(Q1/1D).